Prostate cancer, the second most prevailing cancer among men worldwide, may either progress slowly or rapidly. While in most cases it is slowly progressive, in some cases, it is rapidly progressing resulting in high mortality rate. Prostate-specific imaging techniques is an emergent requirement for early diagnosis and patient-specific therapy.
Besides discussing traditional diagnostic approaches, this review illustrates a perspective on prostate cancer imaging summarizing current imaging approaches with a special focus on prostate specific membrane antigen (PSMA), bombesin (BN) and androgen receptor (AR) targeted imaging using positron emission tomography (PET) and single positron emission computed tomography (SPECT) based on 99mTc and other radiotracers.
Here, the prostate biology is rethought for nuclear imaging as future modality for early, rapid and efficient diagnosis of prostate cancer. Future direction in prostate cancer imaging involves the development of androgen receptor based imaging using nonsteroidal antiandrogen agent for early diagnosis of prostate cancer.
‘Development of androgen receptor based imaging using nonsteroidal antiandrogen agent is the future direction for early diagnosis of prostate cancer, says study.’
